A five-gene signature and clinical outcome in non-small-cell lung cancer
- PMID: 17202451
- DOI: 10.1056/NEJMoa060096
A five-gene signature and clinical outcome in non-small-cell lung cancer
Abstract
Background: Current staging methods are inadequate for predicting the outcome of treatment of non-small-cell lung cancer (NSCLC). We developed a five-gene signature that is closely associated with survival of patients with NSCLC.
Methods: We used computer-generated random numbers to assign 185 frozen specimens for microarray analysis, real-time reverse-transcriptase polymerase chain reaction (RT-PCR) analysis, or both. We studied gene expression in frozen specimens of lung-cancer tissue from 125 randomly selected patients who had undergone surgical resection of NSCLC and evaluated the association between the level of expression and survival. We used risk scores and decision-tree analysis to develop a gene-expression model for the prediction of the outcome of treatment of NSCLC. For validation, we used randomly assigned specimens from 60 other patients.
Results: Sixteen genes that correlated with survival among patients with NSCLC were identified by analyzing microarray data and risk scores. We selected five genes (DUSP6, MMD, STAT1, ERBB3, and LCK) for RT-PCR and decision-tree analysis. The five-gene signature was an independent predictor of relapse-free and overall survival. We validated the model with data from an independent cohort of 60 patients with NSCLC and with a set of published microarray data from 86 patients with NSCLC.
Conclusions: Our five-gene signature is closely associated with relapse-free and overall survival among patients with NSCLC.
Copyright 2007 Massachusetts Medical Society.
Comment in
-
Molecular signatures of lung cancer--toward personalized therapy.N Engl J Med. 2007 Jan 4;356(1):76-8. doi: 10.1056/NEJMe068218. N Engl J Med. 2007. PMID: 17202459 No abstract available.
-
Five-gene signature in non-small-cell lung cancer.N Engl J Med. 2007 Apr 12;356(15):1581-2; author reply 1583. doi: 10.1056/NEJMc070236. N Engl J Med. 2007. PMID: 17429092 No abstract available.
-
Five-gene signature in non-small-cell lung cancer.N Engl J Med. 2007 Apr 12;356(15):1582-3; author reply 1583. N Engl J Med. 2007. PMID: 17436429 No abstract available.
-
Five-gene signature in non-small-cell lung cancer.N Engl J Med. 2007 Apr 12;356(15):1582; author reply 1583. N Engl J Med. 2007. PMID: 17436430 No abstract available.
-
Five-gene signature in non-small-cell lung cancer.N Engl J Med. 2007 Apr 12;356(15):1582; author reply 1583. N Engl J Med. 2007. PMID: 17436431 No abstract available.
-
Five-gene signature in non-small-cell lung cancer.N Engl J Med. 2007 Apr 12;356(15):1582; author reply 1583. N Engl J Med. 2007. PMID: 17436432 No abstract available.
Similar articles
-
Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.Clin Cancer Res. 2008 Nov 15;14(22):7397-404. doi: 10.1158/1078-0432.CCR-07-4937. Clin Cancer Res. 2008. PMID: 19010856
-
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.Clin Cancer Res. 2009 Jan 1;15(1):284-90. doi: 10.1158/1078-0432.CCR-08-1258. Clin Cancer Res. 2009. PMID: 19118056
-
A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.J Natl Cancer Inst. 2006 Jun 21;98(12):825-38. doi: 10.1093/jnci/djj229. J Natl Cancer Inst. 2006. PMID: 16788156
-
Understanding prognostic gene expression signatures in lung cancer.Clin Lung Cancer. 2009 Sep;10(5):331-40. doi: 10.3816/CLC.2009.n.045. Clin Lung Cancer. 2009. PMID: 19808191 Review.
-
Genomic prognostic models in early-stage lung cancer.Clin Lung Cancer. 2009 May;10(3):151-7. doi: 10.3816/CLC.2009.n.021. Clin Lung Cancer. 2009. PMID: 19443334 Review.
Cited by
-
A Novel Network Model for Molecular Prognosis.ACM Int Conf Bioinform Comput Biol (2010). 2010;2010:342-345. doi: 10.1145/1854776.1854825. ACM Int Conf Bioinform Comput Biol (2010). 2010. PMID: 26005718 Free PMC article.
-
Exploration of Prognostic Biomarkers for Lung Adenocarcinoma Through Bioinformatics Analysis.Front Genet. 2021 Apr 22;12:647521. doi: 10.3389/fgene.2021.647521. eCollection 2021. Front Genet. 2021. PMID: 33968130 Free PMC article.
-
Severe testing with high-dimensional omics data for enhancing biomedical scientific discovery.NPJ Syst Biol Appl. 2022 Oct 21;8(1):40. doi: 10.1038/s41540-022-00251-8. NPJ Syst Biol Appl. 2022. PMID: 36271093 Free PMC article.
-
Glycoproteomics using fluid-based specimens in the discovery of lung cancer protein biomarkers: promise and challenge.Proteomics Clin Appl. 2013 Jan;7(1-2):55-69. doi: 10.1002/prca.201200105. Proteomics Clin Appl. 2013. PMID: 23112109 Free PMC article. Review.
-
Key contribution of CPEB4-mediated translational control to cancer progression.Nat Med. 2011 Dec 4;18(1):83-90. doi: 10.1038/nm.2540. Nat Med. 2011. PMID: 22138752
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
